Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nasus Pharma Ltd. (NSRX : AMEX)

• Company Description    Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $8.14 Daily Weekly Monthly 20 Day Moving Average: 38,572 shares Shares Outstanding: 9.06 (millions) Market Capitalization: $73.75 (millions) Beta: 52 Week High: $9.99 52 Week Low: $7.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.12% -0.71% 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL YIGAL ALON 65 - TEL AVIV - YAFO,L3 6744317 ISR ph: 972-3573-6632 fax: - mmoyer@lifesciadvisors.com http://www.nasus-pharma.com

• General Corporate Information    Officers Dan Teleman - Chief Executive Officer Udi Gilboa - Executive Chairman Tair Lapidot - Vice President Ronnie Hershman - Director David Silberman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M7071P109 SIC: - Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 9.06 Most Recent Split Date: (:1) Beta: Market Capitalization: $73.75 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©